Assuming the data is good, they would need to meet with the FDA and confirm they have enough to file for approval, and then yes that would be the next step.
If the data is really good the FDA, could allow conditional/limited use while the application is being reviewed. This has already happened to some degree in Israel.
News 
Market Data 
Discover 
